Keywords: Acute myocardial infarction dementia survival coronary angiography percutaneous coronary intervention a b s t r a c t Objectives: We aimed to (1) study factors that determine the use of invasive procedures in the management of acute myocardial infarction (AMI) in patients with dementia and (2) determine whether the use of invasive procedures was associated with their better survival. Design: Cohort study based on patients registered in the Swedish Dementia Registry (SveDem), 2007e2012. Median follow-up time was 228 days. Setting: Patients diagnosed with dementia in specialist memory clinics and primary care units in Sweden. Participants: A total of 525 patients with dementia who suffered AMI (mean age 89 years, 54% women). Measurements: Information on AMI and use of invasive procedures (coronary angiography and percutaneous coronary intervention) was obtained from Swedish national health registers. Binary logistic regression was applied to study associations of patients' characteristics with the use of invasive procedures; odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Survival was analyzed with Kaplan-Meier curves; log-rank test was used to compare survival of patients who received an invasive procedure versus those who did not receive it. Cox regression was applied to study association of the invasive procedures with all-cause mortality; hazard ratios (HRs) with 95% CIs were calculated. Results: One hundred ten patients (21%) with dementia received an invasive procedure in the management of AMI. After multivariate adjustment, lower age and higher global cognitive status were associated with the use of invasive procedures. The invasively managed patients survived longer (P ¼ .001). The use of invasive procedures was associated with a lower risk of all-cause mortality, adjusting for type of AMI and dementia disorder, age, gender, registration unit, history of AMI and comorbidity score (HR 0.35, 95% CI 0.21e0.59), or total number of drugs (HR 0.34, 95% CI 0.20e0.58). Conclusion: Age and cognitive status determine the use of invasive procedures in patients with dementia. This study suggests that the invasive management of AMI has a benefit for survival of patients with dementia.
Acute myocardial infarction (AMI) is one of the leading causes of death and is particularly prevalent and deadly after 80 years of age. 1, 2 Based on electrocardiographic findings, AMI can present as myocardial infarction with ST-elevation (STEMI) or myocardial infarction without ST-elevation (NSTEMI). 1, 3 NSTEMI is the most common manifestation of AMI in older people, accounting for 75% of AMI cases among patients 80 years and older. 4, 5 Compared to younger individuals, the management of AMI in elderly patients has been traditionally more conservative, mostly because of their comorbidities, higher risk of complications of invasive procedures, cognitive decline, atypical symptoms leading to delayed hospital admission and higher risk of death. 6, 7 Consequently, this can lead to limited access to optimal treatment.
The use of invasive procedures such as coronary angiography and revascularization with percutaneous coronary intervention (PCI) has significantly contributed to improved survival of patients, especially among younger individuals and men. 1, 3, 4 Present guidelines recommend an early invasive strategy for STEMI patients and assessment for the invasive management in patients with NSTEMI. 1, 3 However, coronary angiography and PCI are still not used in all individuals who could benefit from this treatment, possibly because of advanced age, comorbidities, cognitive impairment, or gender. 1,3,8e11 Dementia is an age-related syndrome characterized by progressive cognitive impairment and is associated with lower utilization of coronary angiography and PCI in patients with AMI. 10e13 Because of lack of evidence from randomized clinical trials, reduced life expectancy, and risk of adverse side effects, clinicians face difficult decisions regarding treating AMI in patients with dementia. We aimed to study factors that influence the use of invasive procedures (coronary angiography and PCI) in the management of AMI in patients with dementia and investigate whether the invasive strategy was associated with better survival. Because several studies have suggested that fewer women with AMI are managed invasively, 8, 9 we additionally studied associations of gender with the use of the invasive procedures.
Methods
We performed a cohort study of patients diagnosed with dementia and registered in the Swedish Dementia Registry (SveDem). Data on other diagnoses than dementia, procedures, and drugs were obtained from the Swedish National Patient Register and the Swedish Prescribed Drug Register. Data on death came from the Swedish Population Register.
We studied 29,630 patients who were registered in SveDem between May 1, 2007, and December 31, 2012 . Between the registration to SveDem and the end of follow-up (at death or in December 31, 2012; median 781 days, interquartile range 770 days), 525 patients had a record of AMI as the main diagnosis (flowchart presented on Figure S1 ).
This study complies with the Declaration of Helsinki and was approved by the regional ethical review board in Stockholm, Sweden. Patients were informed of the entry to SveDem and had a possibility to decline participation. Data were deidentified before analysis.
Source of Data
SveDem (www.svedem.se) is a national register that was established on May 1, 2007, with the aim to improve the quality of dementia care in Sweden and was previously described in detail. 14 Briefly, patients are registered by physicians in memory clinics or primary care units at the time of the dementia diagnosis with information about their global cognitive status measured by Mini Mental State Examination (MMSE). In the present study we assigned patients to four groups by the type of dementia disorder: Alzheimer disease (including early and late onset), mixed dementia, vascular dementia and "other dementias" (including dementia with Lewy bodies, Parkinson disease dementia, frontotemporal dementia and unspecified dementia).
The Swedish National Patient Register covers inpatient and outpatient care encounters in Sweden. 15 The diagnoses are coded according to the International Classification of Diseases 10 (ICD 10) and registered at discharge as 1 main diagnosis and up to 21 additional diagnoses. Moreover, the register includes codes for interventional procedures.
The Swedish Prescribed Drug Register contains information on prescribed drugs, coded according to the Anatomical and Therapeutical Classification (ATC), which were dispensed at Swedish pharmacies to the entire Swedish population. 16 
Diagnosis of AMI and Invasive Management
Data on incident cases of AMI were extracted from the Swedish National Patient Register, if the ICD 10 code of AMI was present as the main diagnosis after the registration to SveDem and before December 31, 2012. We did not use AMI codes presented as additional diagnoses to eliminate the risk of including old cases of AMI. We restricted the analyses to the first cases of AMI after the dementia diagnosis. STEMI was defined by codes I21.0eI21.3, NSTEMI by I21.4, and unspecified AMI by I21.9. Invasive management was defined as use of coronary angiography (code AF037) or PCI (codes FNG02 and FNG05), occurring during the hospitalization for AMI. History of AMI was defined by codes I21.0eI21.9, if present at any position in the register at least once between January 1, 2000, and the date of the studied AMI.
Comorbidity and Drugs
We used 9 comorbidities, as suggested for patients with AMI by So and colleagues. 17 We defined them by an ICD 10 code, if present in the Swedish National Patient Register at any position (as main diagnosis or additional diagnoses) at least once between January 1, 2000, and the date of the studied AMI. In addition, we assigned 1 point for each disease and used the sum as a comorbidity score with a maximum of 9 points. The ICD 10 codes are presented in Table S1a .
Information on drugs that were dispensed between July 1, 2005, and August 31, 2013, was extracted from the Swedish Prescribed Drug Register. As in our previous study, 18 the prescription was identified at 7 time points; at the date of registration to SveDem and in 1-year intervals 3 years before and after it. In the present study, we counted the prescription if the ATC code was found at least once from up to 3 years before the registration to SveDem until the date of the studied AMI. Moreover, we used total number of drugs at the time of registration to SveDem as a proxy for overall comorbidity. 19 The ATC codes are presented in Table S1b .
Statistical Analysis
We present descriptive data as means AE standard deviation (SD), median [interquartile range (IQR)] or frequency (n, %), where appropriate. To compare characteristics between groups (STEMI vs NSTEMI vs unspecified AMI; women vs men; invasive management vs no invasive management), we applied an independent sample t test or 1-way analysis of variance (ANOVA) for continuous variables with normal distribution, Mann-Whitney U test, or Kruskal-Wallis test for continuous variables with skewed distribution and chi-square test or Fisher exact test for categorical variables.
To study which factors determine the invasive management of AMI (use of coronary angiography or PCI), we applied binary logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for associations of patients' characteristics with the invasive management. As described above, we used two measures of overall comorbidity (comorbidity score and total number of drugs) and present two models: In model 1, we entered type of AMI, age, gender, MMSE score, history of AMI, registration unit, type of dementia disorder, and comorbidity score.
In model 2, the same variables were entered except that the comorbidity score was replaced by the total number of drugs. Moreover, to study factors that determine the invasive management specifically for patients with STEMI, NSTEMI, and unspecified AMI, we repeated the analyses, while stratified by type of AMI.
To study whether women with AMI are less likely to be managed invasively than men, we applied binary logistic regression to estimate OR with 95% CI for the association of gender with the invasive management. First, we controlled separately for each characteristic (age, type of AMI, MMSE score, history of AMI, type of dementia disorder, registration unit, comorbidity score, and total number of drugs). Second, we controlled simultaneously for age, type of AMI and MMSE scores. Third, we added one comorbidity measure (comorbidity score or total number of drugs) into the model. Fourth, we ran two fully adjusted models: model 1 was adjusted for type of AMI, age, MMSE score, history of AMI, type of dementia disorder, registration unit, and comorbidity score; model 2 had the same variables except that the comorbidity score was replaced by the total number of drugs.
We assessed survival using Kaplan-Meier curves and used log-rank test to compare survival of patients who were managed invasively versus those who were not. We applied Cox regression models to estimate the hazard ratios (HRs) with 95% CIs for the association of the invasive management with all-cause mortality, controlling for type of AMI, age, gender, MMSE score, dementia disorder, registration unit, history of AMI, comorbidity score (model 1), or total number of drugs (model 2). The patients were followed from the time of AMI until death or until the end of follow-up in December 31, 2012, whichever came first. Two-tailed P values of less than .05 were considered to show statistical significance. Data were analyzed using SPSS, version 22 (IBM Corp, Armonk, NY).
Results

Characteristics of the Patients
The study includes 525 patients with dementia (54% women) who were diagnosed with AMI at the mean age of 82 years (Table 1 ). Of those, 110 patients (21%) were managed invasively; coronary angiography was used in 108 and PCI in 84 cases. The diagnosis of STEMI was made in 86 patients, NSTEMI in 235, and unspecified AMI in 204 patients. History of AMI was found in 16% of the patients.
At the time of registration to SveDem, the patients had a mean MMSE score of 22. The majority of the patients (93%) lived in their own homes. Alzheimer disease was diagnosed in 29% of patients, mixed dementia in 21%, vascular dementia in 24%, and "other dementias" in 26%. Before hospitalization for AMI, the most common comorbidity was cardiac dysrhythmia (36%), heart failure (34%), and cerebrovascular disease (26%), and the most frequently prescribed drugs were antithrombotic drugs (73%), beta blockers (56%), and reninangiotensin-aldosterone system (RAAS) antagonists (49%). Overall, the median value of comorbidity score was 1 (IQR 1); 21% of the study population had more than 3 comorbidities. At the time of registration to SveDem, the patients were prescribed a median of 6 (IQR 5) drugs.
Univariate Analysis
The frequency of the invasive management was highest in STEMI patients (55% vs 18% in NSTEMI vs 10% in unspecified AMI; P < .001; Table S2 ). Patients with STEMI were the youngest (80 years old vs 82 years in NSTEMI vs 83.5 years in unspecified AMI; P ¼ .001). The mean MMSE score did not significantly differ by the type of AMI. STEMI patients had the lowest frequency of previous AMI and heart failure and the lowest use of several drugs, such as beta blockers, vasodilators, and lipid-modifying, antithrombotic, and antipsychotic drugs. The highest comorbidity score was found in patients with unspecified AMI, but the distribution of total number of drugs did not significantly differ by the type of AMI.
Women were less often managed invasively (16% of women vs 27% of men; P ¼ .002; Table S2 ) and were older than men (83 years vs 81 years; P < .001; Table S3 ). The difference in the distribution of MMSE score and history of AMI did not significantly differ by gender. Women had a lower frequency of several comorbidities, such as cancer, cerebrovascular diseases, and chronic renal disease. They had been treated to a higher extent with diuretics, antidepressants, hypnotics, and sedatives and to a lower extent with RAAS antagonists and lipid-modifying drugs. Women had a lower comorbidity score than men, but the distribution of total number of drugs did not differ by gender.
Patients who were managed invasively were younger (78 vs 83 years; P < .001; Table S4 ), less frequently women (41% vs 57%; P ¼ .002), and had a higher MMSE score (24 vs 21; P < .001), compared to patients who did not receive any invasive procedure. Moreover, they had a lower frequency of previous AMI, heart failure, cancer, and chronic renal disease and had been prescribed less diuretics and antipsychotic drugs. They had a lower comorbidity score, but did not significantly differ in the total number of drugs.
Multivariate Analysis
Lower age was significantly associated with the invasive management, after controlling for type of AMI, gender, MMSE score, history of AMI, registration unit, type of dementia disorder, and comorbidity score or total number of drugs (OR 0.89, 95% CI 0.85e0.93; Table 2 ; model 1 and model 2). Furthermore, a higher MMSE score was associated with invasive management, after adjustment for type of AMI, gender, age, history of AMI, registration unit, type of dementia disorder, and comorbidity score (OR 1.19, 95% CI 1.11e1.28; model 1) or total number of drugs (OR 1.20, 95% CI 1.12e1.29; model 2).
When stratified by the type of AMI, we found that only higher MMSE score was associated with the invasive management in STEMI patients (Table S5 , model 1 and model 2). In patients with NSTEMI and unspecified AMI, a higher MMSE score as well as lower age was associated with the invasive management in both models. Moreover, total number of drugs was associated with being managed invasively in patients with unspecified AMI (Table S5 , model 2).
Women had lower odds of being managed invasively in unadjusted analysis (OR 0.52, 95% CI 0.34e0.79; Table S6 ). This association slightly attenuated, but remained statistically significant, after controlling separately for type of AMI, age, and MMSE score. However, this became statistically nonsignificant, when type of AMI, age, and MMSE scores were entered into the model simultaneously (OR 0.68, 95% CI 0.41e1.14). In the fully adjusted models, female gender was not associated with the invasive management (model 1: OR 0.63, 95% CI 0.37e1.06; model 2: OR 0.69, 95% CI 0.41e1.16).
Survival After AMI
During the median follow-up time of 228 days (IQR 578), 224 patients (43%) patients died. Among patients who were managed invasively, 89% survived 1 year, whereas only 54% survived 1 year among patients who did not receive invasive management. The invasively managed patients survived longer (log-rank test, P ¼ .001; Figure 1 ). In unadjusted analysis, the invasive management was associated with a lower risk of all-cause mortality (HR 0.30, 95% CI 0.19e0.47; Table 3 ). The association remained statistically significant after controlling for type of AMI, age, gender, type of dementia disorder, registration unit, history of AMI, and comorbidity (model 1: HR 0.35, 95% CI 0.21e0.59; model 2: HR 0.34, 95% CI 0.20e0.58).
Discussion
In this register-based cohort study of patients with dementia, we found that 21% of them received an invasive procedure (coronary angiography or PCI) for the management of AMI. This was most commonly performed in patients with STEMI (55%), less in NSTEMI (18%), and least in those with unspecified AMI (10%). An invasive treatment strategy was associated with lower age and higher global cognitive status, and also with a subsequent lower risk of death.
This study has several limitations. In line with previous reports, 20,21 the number of individuals with dementia hospitalized for AMI is low. Several cases of AMI may have been unrecognized, likely because of patients' inability to verbalize symptoms, atypical presentation of AMI, and a high proportion of silent myocardial infarction. 22, 23 Moreover, patients who died from AMI out of hospital are not captured; it is estimated that 20%e40% of patients with AMI die before they could be hospitalized. 24 As we use administrative data, unrecognized misclassification in the diagnosis of AMI is possible. On the other hand, this study has several strengths. We use two measures of comorbidity that were identified from Swedish health registers, which have almost a complete national coverage. In addition, loss of followup is unlikely, as the outcome (all-cause mortality) was identified through a nationwide register.
We found that invasive management was the most frequent in STEMI patients (55%), reflecting the guidelines recommending an early invasive strategy for those patients. 3 Eighteen percent of NSTEMI patients were managed invasively in our study. Studies performed in the population of octogenarians report that approximately 80% of STEMI and 20%e30% of NSTEMI patients are managed invasively. 25e29 On the other hand, invasive management was used only in 10% of patients with unspecified AMI, who were represented by the oldest individuals with the most comorbidity. The proportion of unspecified AMI in this dementia cohort is higher than in the general population of patients hospitalized for AMI. 30 This suggests diagnostic difficulties as well as limited therapeutic efforts in this group of patients.
This study indicates that severity of cognitive impairment determines the utilization of invasive procedures for management of AMI in patients with dementia. Inadequate communication of symptoms, delays in arrival to the hospital, or initiation of diagnostic procedures may explain this finding. Particularly in patients with NSTEMI and unspecified AMI, higher age was associated with lower odds of being managed invasively, independently of cognitive status and comorbidity. This suggests that advanced age itself limits a possibility of being managed invasively, likely due to atypical presentation of AMI in the oldest patients or personal judgements of physicians about patients' frailty. As opposed to previous reports, 8, 9 this study does not indicate that women have a lower chance of being offered optimal treatment for AMI. In the present study, we found that women were less frequently managed invasively than men; however, this could be explained mainly by their age, cognitive status, and type of AMI.
Previous studies indicate that dementia is a barrier to receiving invasive management for AMI, possibly because of uncertain benefits and insufficient guidance to physicians. 10e13 The oldest old patients have been largely excluded from randomized clinical trials and most observational studies assessing the treatment of AMI in elderly people did not consider dementia/cognition in their analysis. 1, 3 One observational study showed that use of coronary angiography and PCI is associated with lower in-hospital mortality in patients with dementia. 11 The present study, investigating postdischarge survival of patients with dementia, implies that they benefit from the invasive management of AMI and supports its use in this group of patients. Future studies should confirm this finding among patients at a more severe stage of dementia and those who live in nursing homes.
